[go: up one dir, main page]

IN2012DN02345A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02345A
IN2012DN02345A IN2345DEN2012A IN2012DN02345A IN 2012DN02345 A IN2012DN02345 A IN 2012DN02345A IN 2345DEN2012 A IN2345DEN2012 A IN 2345DEN2012A IN 2012DN02345 A IN2012DN02345 A IN 2012DN02345A
Authority
IN
India
Prior art keywords
nucleic acid
stranded
methods
tlrs
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Bruce A Sullenger
Jaewoo Lee
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Publication of IN2012DN02345A publication Critical patent/IN2012DN02345A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN2345DEN2012 2009-09-16 2010-09-16 IN2012DN02345A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24309009P 2009-09-16 2009-09-16
PCT/US2010/002516 WO2011034583A2 (fr) 2009-09-16 2010-09-16 Inhibition de l'activation des récepteurs du type toll endosomaux

Publications (1)

Publication Number Publication Date
IN2012DN02345A true IN2012DN02345A (fr) 2015-08-21

Family

ID=43759220

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2345DEN2012 IN2012DN02345A (fr) 2009-09-16 2010-09-16

Country Status (6)

Country Link
US (3) US9468650B2 (fr)
EP (1) EP2477641B1 (fr)
CN (1) CN102639142A (fr)
CA (1) CA2774460C (fr)
IN (1) IN2012DN02345A (fr)
WO (1) WO2011034583A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682580A1 (fr) 2007-03-30 2008-10-09 Duke University Procede pour moduler l'activite d'une molecule d'acide nucleique
IN2012DN02345A (fr) 2009-09-16 2015-08-21 Univ Duke
US9687529B2 (en) 2011-05-05 2017-06-27 Duke University Method of controlling coagulation
WO2014169043A1 (fr) * 2013-04-09 2014-10-16 Duke University Agents anti-inflammatoires et leurs procédés d'utilisation
US10066323B2 (en) 2014-04-16 2018-09-04 Duke University Electrospun cationic nanofibers and methods of making and using the same
WO2017079537A1 (fr) 2015-11-04 2017-05-11 Duke University Polymères polycationiques destinés à être utilisés dans le traitement et la détection du cancer
CN109982707A (zh) 2016-09-16 2019-07-05 杜克大学 血管性血友病因子（vwf）靶向剂及其使用方法
WO2018119422A1 (fr) 2016-12-22 2018-06-28 Duke University Microfibres polycationiques et leurs procédés d'utilisation
EP3601592A4 (fr) 2017-03-23 2020-11-25 Duke University Inversion médiée par antidote de coloration d'aptamère extracellulaire
US20200171167A1 (en) * 2017-05-30 2020-06-04 The Trustees Of Columbia University In The City Of New York Cationic nucleic acid scavenger and uses thereof
WO2019051397A1 (fr) 2017-09-08 2019-03-14 Duke University Aptamères de ciblage de nucléoline et leurs procédés d'utilisation
WO2021016924A1 (fr) * 2019-07-31 2021-02-04 中山大学 Polymère cationique et particules utilisables pour traiter le psoriasis
EP4249913A1 (fr) * 2022-03-22 2023-09-27 Centre Hospitalier Universitaire de Nîmes Inhibiteur du récepteur de type toll 3 pour la prévention et/ou le traitement de troubles chez des patients ayant des antécédents personnels de thromboembolie veineuse (vte)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919761A (en) 1992-08-14 1999-07-06 The Board Of Regents Of The University Of Michigan Peptides for heparin and low molecular weight heparin anticoagulation reversal
US6037329A (en) 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
JP2004508023A (ja) 2000-09-08 2004-03-18 インビトロジェン　コーポレイション 核酸合成の感度および特異性を増強するための化合物および方法
USRE43612E1 (en) 2000-10-10 2012-08-28 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
WO2002053185A2 (fr) 2001-01-05 2002-07-11 Intercell Ag Utilisations de composes polycationiques
KR20030082961A (ko) 2001-03-08 2003-10-23 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 개질 프로타민
IL159053A0 (en) 2001-05-25 2004-05-12 Univ Duke Modulators of pharmacological agents
AUPR604101A0 (en) 2001-06-29 2001-07-26 Unisearch Limited Aptamers
US20050136040A1 (en) * 2001-10-11 2005-06-23 Imperial College Innovations Limited Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
IL161733A0 (en) 2001-11-02 2005-11-20 Insert Therapeutics Inc Methods and compositions for therapeutic use of rna interference
US20030180250A1 (en) * 2002-03-22 2003-09-25 Council Of Scientific And Industrial Research Compositions and complexes containing a macromolecular compound as potential anti-inflammatory agents
MXPA05003591A (es) 2002-10-09 2005-09-30 Insert Therapeutics Inc Materiales basados en ciclodextrina, composiciones y usos relacionados a los mismos.
US20050256071A1 (en) 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
EP1649019A2 (fr) 2003-07-15 2006-04-26 California Institute Of Technology Acides nucleiques inhibiteurs ameliores
EP2460811A1 (fr) 2004-04-22 2012-06-06 Regado Biosciences, Inc. Modulateurs améliorés de facteurs de coagulation
WO2007001332A2 (fr) * 2004-08-04 2007-01-04 University Of Massachusetts Immunoadhesines anti-pathogene
GB0422877D0 (en) 2004-10-14 2004-11-17 Univ Glasgow Bioactive polymers
AU2006230436B2 (en) 2005-03-31 2011-11-24 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
US7611835B2 (en) 2005-09-30 2009-11-03 Battelle Memorial Institute Process for preparing multilayer enzyme coating on a fiber
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
WO2007140000A2 (fr) 2006-05-26 2007-12-06 Regado Biosciences, Inc. Administration du système d'anticoagulation reg1
EP3669894A3 (fr) * 2006-06-30 2020-08-26 Syntab Therapeutics GmbH Nouveaux composés multifonctionnels à usage pharmaceutique
WO2008066621A2 (fr) 2006-10-19 2008-06-05 Duke University Inhibition de plaquettes réversible
WO2008063157A2 (fr) 2006-10-25 2008-05-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anticoagulant à base de nanoparticules
AU2008216669B2 (en) * 2007-02-15 2013-12-12 Mannkind Corporation A method for enhancing T cell response
CA2682580A1 (fr) * 2007-03-30 2008-10-09 Duke University Procede pour moduler l'activite d'une molecule d'acide nucleique
EP2209552A4 (fr) 2007-09-27 2010-12-08 Sca Hygiene Prod Ab Gels à base d'argile réticulée par un polymère
US20100285081A1 (en) 2007-11-12 2010-11-11 Massachusetts Institute Of Technology Bactericidal Nanofibers, and Methods of Use Thereof
WO2010020008A1 (fr) 2008-08-22 2010-02-25 Polymers Crc Limited Revêtements polymères
WO2010132879A2 (fr) 2009-05-15 2010-11-18 The Johns Hopkins University Polymères cationiques dégradables multicomposants
IN2012DN02345A (fr) 2009-09-16 2015-08-21 Univ Duke
WO2012088059A2 (fr) 2010-12-20 2012-06-28 Virginia Commonwealth University Procédé facile de réticulation et d'incorporation de molécules bioactives dans des échafaudages de fibres électrofilées
US20140234373A1 (en) 2011-09-16 2014-08-21 Georfia Regents University Methods of Promoting Immune Tolerance

Also Published As

Publication number Publication date
CA2774460A1 (fr) 2011-03-24
EP2477641A2 (fr) 2012-07-25
US20170095503A1 (en) 2017-04-06
US20230248805A1 (en) 2023-08-10
US20120183564A1 (en) 2012-07-19
WO2011034583A2 (fr) 2011-03-24
CA2774460C (fr) 2016-08-09
US11617779B2 (en) 2023-04-04
EP2477641A4 (fr) 2013-08-07
EP2477641B1 (fr) 2024-03-27
US9468650B2 (en) 2016-10-18
CN102639142A (zh) 2012-08-15
WO2011034583A3 (fr) 2011-10-06

Similar Documents

Publication Publication Date Title
IN2012DN02345A (fr)
EP2569453A4 (fr) Méthodes d'isolement de l'acide nucléique
WO2020198509A3 (fr) Oligonucléotides modifiés à stabilité accrue
BR112014005205A2 (pt) métodos para etiquetar bibliotecas codificadas com dna
WO2007136736A3 (fr) Procédés de tri et de synthèse d'acides nucléiques
IL190501A0 (en) Multicomponent nucleic acid enzymes and methods for their use
WO2010026488A3 (fr) Procédés et kits de séquençage d'acides nucléiques
IN2014DN03463A (fr)
WO2008063203A3 (fr) Compositions et méthodes de silençage efficace de gènes dans des végétaux
WO2008061537A3 (fr) Oligonucléotides pour moduler l'activité d'arn cible
SG170802A1 (en) Systems and devices for sequence by synthesis analysis
WO2008151631A8 (fr) Utilisation de courts oligonucléotides pour des expériences à redondance de réactif dans une analyse fonctionnelle d'arn
WO2009012363A3 (fr) Nucléotides et aptamères contenant des groupes acide boronique ayant une liaison sollicitée à des protéines glycosylées et leurs utilisations
EP3358014A3 (fr) Procédé de stabilisation d'acides nucléiques fonctionnels
WO2005097993A3 (fr) Oligonucleotides d'arn viral immunostimulateurs
WO2006019430A3 (fr) Procedes et composition pour renforcer l'administration d'arn double brin ou d'acide nucleique hybride double brin pour reguler l'expression genique dans des cellules mammaliennes
EP2647711A3 (fr) Voies d'export alternatives pour l'interférence d'ARN exprimée par vecteur
AR067135A1 (es) Metodos para aislar arn de fragmento largo de muestras fijas
WO2008092081A3 (fr) ADMINISTRATION CIBLÉE D'ARNsi
AU2014219019A8 (en) Short interfering nucleic acid (siNA) molecules containing a 2' internucleoside linkage
EE200200051A (et) Tenastsiin C nukleiinhappelised ligandid
WO2011056073A3 (fr) Composés inédits capables de moduler la néovascularisation et méthodes de traitement faisant appel à ces composés
BR112014021993A2 (pt) detecção da variação de nucleotídeo em sequência de ácido nucleico alvo através de ensaio de clivagem e extensão de pto
ATE548454T1 (de) Nukleinsäurewirkstoffe zur stilllegung von h19 zwecks behandlung rheumatoider arthritis
MX362061B (es) Ácidos nucleicos de enlace c5a nuevos.